APA (7th ed.) Citation

Peters, S., Felip, E., Dafni, U., Tufman, A., Guckenberger, M., Álvarez, R., . . . De Ruysscher, D. (2021). Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). Journal of thoracic oncology, 16(2), 278-288. https://doi.org/10.1016/j.jtho.2020.10.129

Chicago Style (17th ed.) Citation

Peters, Solange, et al. "Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)." Journal of Thoracic Oncology 16, no. 2 (2021): 278-288. https://doi.org/10.1016/j.jtho.2020.10.129.

MLA (9th ed.) Citation

Peters, Solange, et al. "Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)." Journal of Thoracic Oncology, vol. 16, no. 2, 2021, pp. 278-288, https://doi.org/10.1016/j.jtho.2020.10.129.